Pirarubicin is an anthracyclineantibiotics, acts as atopoisomeraseIIinhibitor, and is a widely used for treatment of various cancers, in particular, solid tumors.

Pirarubicin is a topoisomerase II inhibitor^[1]. Pirarubicin shows inhibitory activities against M5076 and Ehrlich cells, with IC₅₀s of 0.366 and 0.078 μM, respectively. The cytotoxicity of Pirarubicin toward M5076 cells is lower than toward Ehrlich cells, and this is due to the much lower expression of topoisomerase II in M5076 cells than in Ehrlich cells^[2]. Pirarubicin (2.5, 5, 10 μg/mL) significantly induces autophagy in a dose dependent manner in bladder cancer (T24, EJ, 5637, J82 and UM-UC-3) cells. Furthmore, Pirarubicin (5 μg/mL) induces apoptosis through inhibition of mTOR/p70S6K/4E-BP1 in bladder cancer cells, and this effect is enhanced by inhibition of autophagy^[3].

Pirarubicin (18 mg/kg, i.v.) significantly elevates serum level of BNP, CK-MB, CTnT, LDH, and MDA compared with those in the control group in acute cardiac toxicity rats. Pirarubicin also lowers heart rate, and depresses R-wave voltage, and prolongation of QT intervals in the acute cardiac toxicity model^[4].

627.64

Solid

C₃₂H₃₇NO₁₂

72496-41-4

吡柔比星；吡喃阿霉素；吡柔吡星

Room temperature in continental US; may vary elsewhere.

4°C, protect from light

*该产品在溶液状态不稳定，建议您现用现配，即刻使用。

DMSO : 10 mg/mL(15.93 mM;ultrasonic and warming and heat to 80℃)

请根据产品在不同溶剂中的溶解度，选择合适的溶剂配制储备液；该产品在溶液状态不稳定，建议您现用现配，即刻使用。